膀胱癌新靶标大样本多中心检测

Abstract

膀胱癌是泌尿系最常见的恶性肿瘤。我们开发了一种膀胱癌新靶标检测试剂盒,用于检测人尿中异常糖基化整合素(AG31)。我们分析了来自中国多个中心的3000余例膀胱癌(BC)、肾细胞癌(RCC)、前列腺癌(PC)、膀胱炎、肾炎和前列腺炎患者的尿液样本。采用受试者工作特性曲线(ROC)来确定诊断的准确性。膀胱癌患者的尿液标本中AG31水平明显高于任何对照组。此外,尿液中AG31水平的升高可以区分膀胱癌和良性炎症性疾病。尿AG31试验比尿核基质蛋白(NMP22)试验更敏感和特异性。因此,尿AG31测定将为膀胱癌检测提供一种理想的标志物。

References

Siegel R, Ma J, Zou Z, et al., 2014, Cancer Statistics, 2014. CA Cancer J Clin, 64: 9-29.

Babjuk M, Burger M, Zigeuner R, et al., 2013, EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder: Update 2013. Eur Urol, 64: 639-53.

Knowles MA, Hurst CD, 2015, Molecular Biology of Bladder Cancer: New Insights into Pathogenesis and Clinical Diversity. Nat Rev Cancer, 15: 25-41.

Kaufman DS, Shipley WU, 2009, Feldman AS, Bladder Cancer. Lancet, 374: 239-249.

Babjuk M, 2011, What are the Limitations of Endoscopic Management of Urothelial Carcinoma of the Upper Urinary Tract? Eur Urol, 60: 961-963.

Xylinas E, Kluth LA, Lotan Y, et al., 2014, Blood- and Tissue-Based Biomarkers for Prediction of Outcomes in Urothelial Carcinoma of the Bladder. Urol Oncol, 32: 230-242.

Kandimalla R, Masius R, Beukers W, et al., 2013, A 3-Plex Methylation Assay Combined with the FGFR3 Mutation Assay Sensitively Detects Recurrent Bladder Cancer in Voided Urine. Clin Cancer Res, 19: 4760-4769.

Kinde I, Munari E, Faraj SF, et al., 2013, TERT Promoter Mutations Occur Early in Urothelial Neoplasia and are Biomarkers of Early Disease and Disease Recurrence in Urine. Cancer Res, 73: 7162-7167.

Margulis V, Lotan Y, Karakiewicz PI, et al., 2009, Multi-Institutional Validation of the Predictive Value of ki-67 Labeling Index in Patients with Urinary Bladder Cancer. J Natl Cancer Inst, 101: 114-119.

Stoeber K, Swinn R, Prevost AT, et al., 2002, Diagnosis of Genito-Urinary Tract Cancer by Detection of Minichromosome Maintenance 5 Protein in Urine Sediments. J Natl Cancer Inst, 94: 1071-1079.

Winograd-Katz SE, Fässler R, Geiger B, et al., 2014, The Integrin Adhesome: From Genes and Proteins to Human Disease. Nat Rev Mol Cell Biol, 15: 273-288.

Sachs N, Sonnenberg A, 2013, Cell-Matrix Adhesion of Podocytes in Physiology and Disease. Nat Rev Nephrol, 9: 200-210.

Liu Y, Chattopadhyay N, Qin S, et al., 2009, Coordinate Integrin and c-met Signaling Regulate Wnt Gene Expression During Epithelial Morphogenesis. Development, 136: 843-853.

Lityńska A, Przybyło M, Ksiazek D, et al., 2000, Differences of alpha3beta1 Integrin Glycans from Different Human Bladder Cell Lines. Acta Biochim Pol, 47: 427-434.

Brooks CL, Schietinger A, Borisova SN, et al., 2010, Antibody Recognition of a Unique Tumor-Specific Glycopeptide Antigen. Proc Natl Acad Sci USA, 107: 10056-10061.

Park JH, Nishidate T, Kijima K, et al., 2010, Critical Roles of Mucin 1 Glycosylation by Transactivated Polypeptide N-Acetylgalactosaminyltransferase 6 in Mammary Carcinogenesis. Cancer Res, 70: 2759-2769.

Li C, Yang Z, Du Y, et al., 2014, BCMab1, a Monoclonal Antibody Against Aberrantly Glycosylated Integrin α3β1, has Potent Antitumor Activity of Bladder Cancer in vivo. Clin Cancer Res, 20: 4001-4013.

Watanabe H, Satake A, Kido Y, et al., 2002, Monoclonal Based Enzyme-Linked Immunosorbent Assay and Immunochromatographic Assay for Enrofloxacin in Biological Matrices. Analyst, 127: 98-103.

Yu F, Yu S, Yu L, et al., 2014, Determination of Residual Enrofloxacin in Food Samples by a Sensitive Method of Chemiluminescence Enzyme Immunoassay. Food Chem, 149: 71-75.

Mostofi FK, Sobin LH, Torloni H, et al., 1973, Histological Typing of Urinary Bladder Tumours. Mostofi FK in collaboration with Sobin LH, Torloni H and pathologists in fourteen countries. Geneva: World Health Organization.

Chen Z, Ding W, Xu K, et al., 2012, The 1973 WHO Classification is more Suitable than the 2004 WHO Classification for Predicting Prognosis in Non-Muscle-Invasive Bladder Cancer. PLoS One, 7: e47199.

American Joint Committee on Cancer, 2002, AJCC Cancer Staging Handbook: From the AJCC Cancer Staging Manual. 6th ed., Springer, New York.

Gupta K, Hooton TM, Naber KG, et al., 2011, International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis, 52: e103-20.

Schaeffer AJ, Knauss JS, Landis JR, et al., 2002, Leukocyte and Bacterial Counts do not Correlate with Severity of Symptoms in Men with Chronic Prostatitis: The National Institutes of Health Chronic Prostatitis Cohort Study. J Urol, 168: 1048-1053.

Müller A, Mulhall JP, 2005, Sexual Dysfunction in the Patient with Prostatitis. Curr Opin Urol, 15: 404-409.

Mitra AP, Cote RJ, 2009, Molecular Pathogenesis and Diagnostics of Bladder Cancer. Annu Rev Pathol, 4: 251-285.

Cheung G, Sahai A, Billia M, et al., 2013, Recent Advances in the Diagnosis and Treatment of Bladder Cancer. BMC Med, 11: 13.

Yossepowitch O, Herr HW, Donat SM, 2007, Use of Urinary Biomarkers for Bladder Cancer Surveillance: Patient Perspectives. J Urol, 177: 1277-1282.

Ardelt P, Grünemay N, Strehl A, et al., 2013, LASP-1, a Novel Urinary Marker for Detection of Bladder Cancer. Urol Oncol, 31: 1591-1598.

Kelly JD, Dudderidge TJ, Wollenschlaeger A, et al., 2012, Bladder Cancer Diagnosis and Identification of Clinically Significant Disease by Combined Urinary Detection of Mcm5 and Nuclear Matrix Protein 22. PLoS One, 7: e40305.

Shariat SF, Karakiewicz PI, Palapattu GS, et al., 2006, Outcomes of Radical Cystectomy for Transitional Cell Carcinoma of the Bladder: A Contemporary Series from the Bladder Cancer Research Consortium. J Urol, 176: 2414-2422.

Barbieri CE, Cha EK, Chromecki TF, et al., 2012, Decision Curve Analysis Assessing the Clinical Benefit of NMP22 in the Detection of Bladder Cancer: Secondary Analysis of a Prospective Trial. BJU Int, 109: 685-690.

Mowatt G, Zhu S, Kilonzo M, et al., 2010, Systematic Review of the Clinical Effectiveness and Cost-effectiveness of Photodynamic Diagnosis and Urine Biomarkers (FISH, ImmunoCyt, NMP22) and Cytology for the Detection and Follow-up of Bladder Cancer. Health Technol Assess, 14: 1–331.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.